Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era.

Autor:	Oertel M; Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany., Hering D; Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany., Nacke N; Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany., Kittel C; Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany., Kröger K; Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany., Kriz J; Department of Radiation Oncology, Alexianer Clemenshospital Muenster, Muenster, Germany., Fuchs M; Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne, Düsseldorf, University Hospital of Cologne, Cologne, Germany., Baues C; Department of Radiation Oncology and Cyberknife Center, University Hospital of Cologne, Cologne, Germany., Vordermark D; Department of Radiation Oncology, University Hospital Halle (Saale), Halle (Saale), Germany., Engenhart-Cabillic R; Department of Radiotherapy and Radiation Oncology, University Hospital Giessen-Marburg, Marburg, Germany., Herfarth K; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany., Lukas P; Department of Radiooncology, Medical University Innsbruck, Innsbruck, Austria., Schmidberger H; Department of Radiotherapy and Radiation Oncology, University Hospital Mainz, Mainz, Germany., Marnitz S; Department of Radiation Oncology and Cyberknife Center, University Hospital of Cologne, Cologne, Germany., Borchmann P; Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne, Düsseldorf, University Hospital of Cologne, Cologne, Germany., Engert A; Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne, Düsseldorf, University Hospital of Cologne, Cologne, Germany., Haverkamp U; Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany., Eich HT; Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany.
Jazyk:	angličtina
Zdroj:	Advances in radiation oncology [Adv Radiat Oncol] 2022 Dec 30; Vol. 8 (3), pp. 101169. Date of Electronic Publication: 2022 Dec 30 (Print Publication: 2023).
DOI:	10.1016/j.adro.2022.101169
Abstrakt:	Purpose: Radiation therapy (RT) is an integral part of treatment concepts for early-stage Hodgkin lymphoma. This analysis reports on RT quality in the recent HD16 and 17 trials of the German Hodgkin Study Group (GHSG). Methods and Materials: All RT plans of involved-node radiation therapy (INRT) in HD 17 were requested for analysis, along with 100 and 50 involved-field radiation therapy (IFRT) plans in HD 16 and 17, respectively. A structured assessment regarding field design and protocol adherence was performed by the reference radiation oncology panel of the GHSG. Results: Overall, 100 (HD 16) and 176 (HD 17) patients were eligible for analysis. In HD 16, 84% of RT series were evaluated as correct, with significant improvement compared with the predecessor studies ( P < .001). In HD 17, 76.1% of INRT cases revealed a correct RT design compared with 69.0% of IFRT-cases, which was superior to previous studies ( P < .001). Comparing INRT and IFRT, we found no significant differences in the percentage of any deviation ( P  = .418) or major deviations ( P  = .466). Regarding dosimetry, INRT was accompanied by an improvement in thyroid doses. Comparing different RT techniques, we found that intensity-modulated RT showed a reduction of high doses in the lung at the expense of an increased low-dose exposure in HD 17. Conclusions: The latest study generation of the GHSG demonstrates an improved quality in RT. A modern INRT design could be established without deterioration in quality. On a conceptual level, an individual consideration of the appropriate RT technique has to be performed. (© 2022 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu